GENPREX INC (GNPX) Stock Price, Forecast & Analysis
USA - NASDAQ:GNPX - US3724462037 - Common Stock
GNPX Key Statistics, Chart & Performance
The current stock price of GNPX is 4.18 USD. In the past month the price decreased by -58.97%. In the past year, price decreased by -94.57%.
GNPX Latest News, Press Relases and Analysis
GNPX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.96 | 383.36B | ||
| AMGN | AMGEN INC | 14.69 | 172.98B | ||
| GILD | GILEAD SCIENCES INC | 14.32 | 145.55B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.8 | 105.91B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.55 | 69.41B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 876.39 | 58.59B | ||
| INSM | INSMED INC | N/A | 39.46B | ||
| NTRA | NATERA INC | N/A | 28.53B | ||
| BIIB | BIOGEN INC | 9.21 | 22.61B | ||
| INCY | INCYTE CORP | 16.3 | 20.44B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.17 | 20.49B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.2 | 14.59B |
Related stock screener links
About GNPX
Company Profile
Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company is headquartered in Austin, Texas and currently employs 15 full-time employees. The company went IPO on 2018-03-29. The firm's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.
Company Info
GENPREX INC
3300 Bee Cave Road, Suite 650-227
Austin TEXAS 78712 US
CEO: J. Rodney Varner
Employees: 15
Phone: 18777744679
GENPREX INC / GNPX FAQ
What does GENPREX INC do?
Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company is headquartered in Austin, Texas and currently employs 15 full-time employees. The company went IPO on 2018-03-29. The firm's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.
What is the stock price of GENPREX INC today?
The current stock price of GNPX is 4.18 USD. The price decreased by -0.71% in the last trading session.
Does GENPREX INC pay dividends?
GNPX does not pay a dividend.
How is the ChartMill rating for GENPREX INC?
GNPX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the upcoming earnings date for GENPREX INC?
GENPREX INC (GNPX) will report earnings on 2025-11-11, after the market close.
GNPX Technical Analysis
GNPX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GNPX. GNPX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GNPX Financial Highlights
Over the last trailing twelve months GNPX reported a non-GAAP Earnings per Share(EPS) of -18.38. The EPS increased by 2.49% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -518.59% | ||
| ROE | -1320.11% | ||
| Debt/Equity | 0 |